EGFR exon 19 deletion
1 drugsPredictive biomarker for patient selection in 5 indications
1
Approved Drugs
5
Indications
1
Companies
EGFR exon 19 deletion is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 5 indications including Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer. Explore the targeted therapies, indications, testing methods, and companies developing EGFR exon 19 deletion drugs below.
Search EGFR exon 19 deletion Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting EGFR exon 19 deletion
| Drug | Company | Therapeutic Area |
|---|---|---|
| CYRAMZA | Eli Lilly | Oncology |
EGFR exon 19 deletion Indications
Gastric Cancer Gastroesophageal Junction Adenocarcinoma Non-Small Cell Lung Cancer Colorectal Cancer Hepatocellular Carcinoma